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Abstract
Background: Hepatitis C virus (HCV) encodes two transmembrane glycoproteins E1 and E2 which form
a heterodimer. E1 is believed to mediate fusion while E2 has been shown to bind cellular receptors
including CD81. In this study, alanine substitutions in E2 were generated within putative CD81 binding
regions to define residues critical for viral entry. The effect of each mutation was tested by challenging
susceptible cell lines with mutant HCV E1E2 pseudotyped viruses generated using a lentiviral system
(HCVpp). In addition to assaying infectivity, producer cell expression and HCVpp incorporation of HCV
E1 and E2 proteins, CD81 binding profiles, and E1E2 association of mutants were examined.
Results: Based on these characteristics, mutants either displayed wt characteristics (high infectivity [≥
50% of wt HCVpp], CD81 binding, E1E2 expression, association, and incorporation into viral particles and
proper conformation) or segregated into 4 distinct low infectivity (≤ 50% of wt HCVpp) mutant
phenotypes: (I) CD81 binding deficient (despite wt E1E2 expression, incorporation and association and
proper conformation); (II) CD81 binding competent, but lack of E1 detection on the viral particle, (despite
adequate E1E2 expression in producer cell lysates and proper conformation); (III) CD81 binding
competent, with adequate E1E2 expression, incorporation, association, and proper E2 conformation (i.e.
no defect identified to explain the reduced infectivity observed); (IV) CD81 binding deficient due to
disruption of E2 mutant protein conformation.
Conclusion: Although most alanine substitutions within the putative CD81 binding region 1 (amino acids
474–492) displayed greatly reduced HCVpp infectivity, they retained soluble CD81 binding, proper E2
conformation, E1E2 association and incorporation into HCVpp suggesting that region 1 of E2 does not
mediate binding to CD81. In contrast, conformationally correct E2 mutants (Y527 and W529) within the
second putative CD81 binding region (amino acids 522–551) disrupted binding of E2 to CD81-GST,
suggesting that region 2 is critical to CD81 binding. Likewise, all conformationally intact mutants within the
third putative CD81 binding region (amino acids 612–619), except L615A, were important for E2 binding
to CD81-GST. This region is highly conserved across genotypes, underlining its importance in mediating
viral entry.
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Background
Hepatitis C virus (HCV) is a primary causative agent of
chronic hepatitis. It is a positive-strand RNA virus in the
family Flaviviridae that encodes a polyprotein of approxi-
mately 3,000 amino acids. This polyprotein is cleaved
into ten viral proteins including two transmembrane
envelope glycoproteins, E1 and E2, which are heavily N-
glycosylated in their N-terminal ectodomains. Like other
Flaviviruses, the interactions of the E1 and E2 glycopro-
teins with cell surface receptors mediate HCV entry via
receptor mediated endocytosis [1]. It is believed that E1
mediates fusion of the membranes and E2 binds the cel-
lular receptors, but it is not clear whether the fusion pep-
tide resides in E1 or E2 [2].
Several cellular surface molecules have been implicated in
HCV entry, including: CD81 [3-6], scavenger receptor
class B type I (SR-BI) [7-9], the low-density lipoprotein
receptor (LDLR) [10,11], Claudin-1,6 and 9 [12-14], den-
dritic-cell-specific intercellular adhesion molecule 3-grab-
bing nonintegrin (DC-SIGN) [15-17] and Liver/lymph
node-specific intercellular adhesion molecule-3-grabbing
integrin (L-SIGN) [18,19]. While L-SIGN and DC-SIGN
are not expressed on hepatocytes, it is believed that den-
dritic cells expressing these molecules facilitate persistent
infection by capturing and delivering the virus to the liver
[18,19]. SR-BI is a multiligand receptor that binds several
lipoproteins, including HDL, LDL and VLDL. It is prima-
rily expressed in the liver and facilitates the uptake of lip-
ids [20,21]. In infected patient's sera, HCV is found
associated with LDL and VLDL, leading to the hypothesis
that HCV may be "hitching a ride" with the lipoproteins
to infect susceptible cells via lipoprotein receptors.
The role and requirement for CD81 in HCV entry has
been thoroughly characterized and documented [3-
6,22,23]. CD81 is a non-glycosylated, membrane bound
protein characterized by four transmembrane domains
and a small (SEL) and large (LEL) extracellular loop [24-
28]. This protein is present on virtually all nucleated cells.
Experiments establishing a definitive role for CD81 in
HCV infection have been achieved using the retroviral
pseudoparticle (HCVpp) and the recently developed in
vitro HCV infectious clone systems [29-32]. The LEL of
CD81 has been identified as the binding region of HCV
E2 and critical amino acids for maintaining this interac-
tion have been determined [33,34]. On the other hand,
while several putative CD81 binding regions of HCV E2
have been identified, the critical amino acids of the E2
protein that bind CD81 are not well defined. The first pro-
posed region spans the second hypervariable domain,
extending from amino acid 474–492 [35-39]. The second
region identified spans position 522–551 [35-39] and the
third region is between amino acids 612–619 [35,36].
Notably, the amino acid composition of these regions var-
ies significantly between individual viral genomes
because HCV undergoes rapid genetic change requiring
classification into multiple, naturally occurring geno-
types. Amino acid sequences between these different gen-
otypes vary approximately 30% and even within a single
genotype, differences can range from 5–10% [40]. Thus,
within HCV-infected individuals, the virus exists as a qua-
sispecies. This is presumably due to both the random,
high error rate of viral RNA polymerase as well as immune
pressure [41]. Because the E2 glycoprotein varies so much,
identifying conserved residues within these putative
regions that are critical for maintaining the interaction
between CD81 and HCV, might provide important
insight not only for elucidating the molecular mechanism
of viral entry, but also for developing entry inhibitors as a
novel therapeutic option.
In this study, to define residues critical for viral entry, indi-
vidual alanine substitutions in the three putative CD81
binding regions were generated via site-directed mutagen-
esis. The strategy was to target residues that are highly con-
served across several strains of HCV, as retention of
specific residues across genetically diverse genotypes
strongly implicates those residues as being important for
the interaction between HCV E2 and CD81. Although the
hypervariable region II (HVR II) extends into the first
putative CD81 binding region targeted (residues 474–
482), residues Y474 and D481 are very highly conserved
and were therefore also targeted in this study. Susceptible
cell lines were challenged with HCV E1E2 pseudovirus
(HCVpp) containing the individual mutations to deter-
mine the effect of each mutation on HCVpp infectivity.
Additionally, producer cell expression and HCVpp incor-
poration of HCV E1 and E2 proteins, CD81 binding pro-
files, conformation and E1E2 association of mutants were
also examined.
Results
Identification of highly conserved, charged, hydrophobic 
residues within the putative CD81 binding regions of E2
Three putative CD81 interaction sites on HCV E2 have
been previously identified; region 1, 474–492 [35-39];
region 2, 522–551 [35-39]; and region 3, 612–619
[35,36]. Remarkably, although E2 is subject to strong
immune selective pressure in vivo, sequence alignment
indicates that there is a high degree of sequence conserva-
tion within these three regions, consistent with the idea of
these regions having functional importance. Among the
three putative CD81-binding regions, region 3 (residues
612–619) is the most conserved, while region 1 (residues
474–492) has the greatest sequence variability, which is
expected as the second hypervariable region (HVR II)
extends into positions 474–482 (Fig. 1). Although within
the HVR II, amino acids Y474 and D481 are still veryVirology Journal 2008, 5:46 http://www.virologyj.com/content/5/1/46
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highly conserved and were therefore targeted. Being inter-
ested in identifying amino acids that directly mediate
HCV E2 protein-protein interactions with CD81, we
decided to focus in large part on charged, hydrophobic
residues conserved in these regions.
Effect of E2 alanine substitutions on the infectivity of 
HCVpp
To identify which of the charged, conserved amino acids
in the three putative CD81 interaction sites of E2 are crit-
ical for infectivity, a panel of alanine substitutions was
generated within the context of H77 E2 (Fig. 1 and Fig. 2).
The substitutions are numbered based on their position
within the polyprotein of the H77 clone and use the one
letter amino acid code to denote the amino acid present at
the site prior to alanine substitution. After sequence con-
firmation of the alanine substitutions, HCVpp infectivity
of permissive Huh7 and Hep3B cells was assessed by inoc-
ulating cells with HIV virions pseudotyped with either wt
E1E2 or the mutant E1E2 glycoproteins (Fig. 2). While
Huh7 cells support robust HCV infection in vitro [29-32]
and are thus obviously a relevant cell lines for this analy-
sis, confirmatory screening was also performed in Hep3B
cells, which have been shown to be permissive for HCVpp
entry. Infectivity was determined as a measure of luci-
ferase activity. In these experiments, VSVG/HIV virions
were used as a positive control. As expected, infection of
the cells by VSVG/HIV virus leads to a high level of luci-
ferase activity (~107 RLU) (Fig. 2). Infection of the target
cells by wt HCV E1E2/HIV virus resulted in luciferase lev-
Conserved residues within the putative CD81 binding domains of E2 Figure 1
Conserved residues within the putative CD81 binding domains of E2. HCV strains from the Los Alamos HCV 
sequence database were aligned. Three regions previously implicated in CD81 binding were analyzed. Amino acids are num-
bered relative to the AUG start codon of the H77 strain shown and used in this study. The hyperconserved (black rectangles) 
targeted (asterisk) residues for alanine substitution are indicated.
Putative CD81 BINDING REGION 1__________________________________________
474        481   483   485   487  488  489    492 
*        *   *   *   *  *  *    * 
Y   A   N   G   S   G   L   D   E   R   P   Y   C   W   H   Y   P   P   R
Putative CD81 BINDING REGION 2________________________________________________________________    
522      527   529     533   535             
     *    *      *    *
S G A P T Y S W G A N D T D V F V L N N T R P P
______________
   549  550
   *  * 
L  G N W F  GG 
Putative CD81 BINDING REGION 3___
612 613 614 615 616 617 618   619 
  * * * * * * 
P Y R L W  H Y P CVirology Journal 2008, 5:46 http://www.virologyj.com/content/5/1/46
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Alanine substitutions within putative CD81 binding regions dramatically affect HCVpp entry Figure 2
Alanine substitutions within putative CD81 binding regions dramatically affect HCVpp entry. 293T cells were 
cotransfected with the HIV-luc packaging vector along with HCV E1E2 mutant expression plasmids. HCVpp was harvested at 
24 h post-transfection and used to infect susceptible cell lines (A) Huh7 and (B) Hep3B. Infectivity was measured 72 h pi using 
a luciferase reporter assay. Infectivity of each mutant is expressed as a percentage of the infectivity observed for the wild-type 
(wt) H77 HCV E1E2. Values shown are the mean and standard error for a minimum of three assays.
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els at least 2 log above a negative control, EnvA/HIV [42].
In the first putative CD81 binding region, two mutations
at positions 474 and 481 retained a significant degree of
infectivity relative to that of wt HCVpp E1E2 control.
D481A demonstrated quantitatively similar infectivity in
both Huh7 (Fig 2A) and Hep3B (Fig. 2B) cells (64% and
71% respectively), compared to wt. While mutant Y474A
retained a higher percent infectivity in the Huh7 cells
(76%) compared to Hep3B cells (36%), in both cell lines
Y474A exhibited one of the highest levels of infectivity
among the mutants tested. In contrast to these 2 mutants,
the remaining alanine substitutions within the first puta-
tive CD81 binding region reduced infectivity to 5% or less
of wt in both Huh7 and Hep3B cells. In the second puta-
tive CD81 binding region, alanine substitution of con-
served residues severely decreased infectivity in both cell
lines. While the predominant phenotype of mutations in
the putative CD81 binding region 2 was ablation of infec-
tion, the D533A and F550A mutants did retain some
detectable level of infectivity in Huh7 cells, 12 and 19%
respectively. However this minimal level of infection was
not detected in the Hep3B cell assay, confirming the sever-
ity of the infectivity defect associated with changes in
these residues. Finally, in the third putative CD81 binding
region, all mutations, with the exception of L615A,
impaired infectivity below 4%. As seen with the Y474A
mutation in region 1, the exact amount of infectivity
exhibited by L615A varied between cell lines with 44% of
wt levels observed in Huh7 compared to 10% of wt levels
observed in Hep3B cells; however, the trend of reduced
infectivity was consistent.
Notably, the infectivity trend observed for all the mutants
was the same in both Huh7 and Hep3B cells, indicating
the importance of these specific conserved HCV E2 resi-
dues for HCV entry in both cell types. Interestingly how-
ever, with the exception of D481A, all mutations
maintained a higher level of infection in Huh7 cells com-
pared to Hep3B, even though the baseline of HCV wt
infectivity was slightly higher in Hep3B. This was particu-
larly evident for the Y474A and L615A mutations noted
above which exhibited 76% and 44% infectivity respec-
tively in Huh7 cells compared to 36% and 10% infectivity
in Hep3B cells. It remains to be determined if these quan-
titative differences are informative.
Expression and incorporation of HCV E1E2 mutants
To confirm adequate expression of the various E2 alanine
substitutions, mutant E2 protein levels in the 293T pro-
ducer cell lysates transiently transfected with HIV-luc
backbone and the HCV E1E2 glycoprotein plasmids were
examined by Western Blot analysis. Actin levels were used
as a control for protein loading. When probed with anti-
E2 antibody, a band of ~70kDa was detected in the cell
lysate of wt and all mutant glycoprotein transfected cells,
corresponding to the size of the HCV E2 protein (Fig. 3A).
Overall, cell lysate levels of E2 were reduced for the
mutants in the putative CD81 binding regions 2 and 3,
compared to region 1 (Fig. 3A). To determine if this
reduced intracellular expression has an effect on E1E2
incorporation onto the viral particle, virions were pelleted
through a 20% sucrose cushion and examined by Western
Blot, probing for p24 capsid levels to control for pseudo-
virus particle loading. E2 extracted from the viral particle
displayed a diffuse migration pattern with at least three
distinct bands, most likely due to extensive N-linked glyc-
osylation (Fig. 3B)[43]. These various forms of E2 were
incorporated into particles regardless of the specific E2
mutation present and independent of the intracellular
accumulation levels of the protein (Fig. 3A). Hence, the
lower intracellular E2 levels detected for the mutants in
regions 2 and 3 were not reflected in the amount of E2
incorporated into the viral particle. Levels of E1 detected
on the various mutant viral particles however, varied
greatly. Most dramatically, although E2 incorporation was
not impaired, E1 was not detected in W487A or W549A
mutant viral particles. This could either be due to the loss
of the monoclonal antibody epitope the Western Blot was
probed with or due to a lack of incorporation onto the
viral particle. Based on these two E2 mutations coming
down in the conformational antibody immunoprecipita-
tion (Fig. 4B), we suspect E1 is present on HCVpp since
both E1 and E2 need to be present for proper folding [44].
In any case, the level of E1 detected on the different
mutant viral particles did not correlate with infectivity lev-
els or correspond to a specific binding region. At the posi-
tions where greater levels of E1 were detected, the bands
appeared as a couplet.
Characterization of E2 mutant CD81 binding
Although E1 and mutant E2 glycoproteins were detected
on viral particles except W487A and W549A, infectivity
was nonetheless severely impaired in most of them. To
establish if this was due to disruption of CD81 binding, as
predicted based on the previous identification of these
regions as putative CD81 binding domains, the binding
of the mutants to recombinant soluble CD81-LEL [4] was
assayed. In these experiments, binding of HCV E1E2 pro-
teins to a purified GST tag was used as a control. Unex-
pectedly, twelve of the twenty mutants bound soluble
CD81 at levels similar to wt, including all the mutations
in the putative CD81 binding region 1 (Y474A, D481A,
R483A, Y485A, W487A, H488A, Y489A, and R492A) sug-
gesting that this region is not directly involved in binding
CD81 (Fig. 4A). The fact that HCVpp infectivity was
severely reduced in response to all region 1 mutants
except Y474A and D481A, therefore suggests that this
region likely plays another role in the viral entry process.
On the other hand, while several of the mutations in
regions 2 and 3 (D533A, W549A, F550A, and L615A)Virology Journal 2008, 5:46 http://www.virologyj.com/content/5/1/46
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retained the ability to bind CD81, indicating that these
specific residues are also not directly involved in the E2
and CD81 interaction, eight of the substitution mutants
in these domains did not bind CD81 (Fig. 4A), consistent
with the involvement of regions 2 and 3 in CD81 binding.
Specifically, mutants W529A, D535A, Y613A, R614A,
W616A and H617A did not bind soluble CD81 at all, and
two mutants, Y527A and Y618A, exhibited dramatically
reduced interaction with CD81.
To confirm that loss of CD81 binding was not due to a
more general disruption of E2 structure in this region of
the protein, we performed immunoprecipitation of CD81
binding deficient mutants with an antibody that recog-
nizes a conformational epitope within the putative CD81
binding regions 2 and 3 [45]. Wt and the CD81 binding
competent D533A mutants as well as W487A and W549A,
for which we did not detect E1 on the viral particle, were
captured with the conformational antibody, consistent
with proper folding. While the Y527A, W529A, Y613A,
H617A and Y618A E2 mutants were all deficient for CD81
binding, they too were recognized by the conformation-
dependent antibody, indicating their conformation
remained in tact. This strongly implicates these five resi-
dues as being critical for CD81 binding. In contrast, three
of the mutations that did not bind CD81, (D535A, R614A
and W616A) did not come down in the immunoprecipi-
tation assay, suggesting mutations in these residues might
have resulted in more global changes in E2 conformation.
While loss of AR3A binding could also be due to changes
in specific amino acids within the AR3A epitope, for the
moment we consider these mutants as uninformative
because the overall structure of the protein might be com-
promised.
Expression and incorporation of HCV E1E2 glycoproteins in producer cell lysate and HCVpp Figure 3
Expression and incorporation of HCV E1E2 glycoproteins in producer cell lysate and HCVpp. (A) 293T HCVpp 
producer cells were lysed and analyzed by Western Blot analysis using anti (α)-E2 and (α)-actin antibodies. Image is a compos-
ite. (B) Incorporation of HCV glycoproteins into HCVpp was determined by pelleting the virus through a 20% sucrose cushion 
followed by Western Blot analysis. HCV glycoproteins were identified with (α)-E2 and (α)-E1 antibodies. Detection of the HIV 
p24 capsid protein with an anti-HIV p24 antibody was performed as a loading control. Image is a composite.
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Analysis of E1 and E2 association
Having identified several E2 mutations that exhibit
severely reduced infectivity while retaining the ability to
bind CD81, we next investigated whether any of the
alanine substitutions in E2 disrupted E1E2 association. It
is known that E1 and E2 must properly dimerize in order
to mediate HCV infectivity [2,43,46-49]. This is a relevant
consideration for these mutations as E2 dimerization
domains have been mapped to the transmembrane
domains, a WHY motif at positions 487–489, amino acids
415–500 as well as amino acids L675, S678, L689 and
L692 [48,50-53]. For this analysis, 293T cells were tran-
siently transfected with the HCV glycoprotein constructs
then lysed 48 h later. E2 protein was pulled down with
polyclonal HCV E2 antibody and immunocomplexes
were analyzed by Western Blot for the presence of E1
using a monoclonal antibody. To control for E2 antibody
specificity, 293T cells were also transfected with E1 alone.
For several mutants, most notably W549A, F550A and
R614A, a greater amount of E2 was detected compared to
wt (Fig. 5). Notably however, despite varying levels of E2
pulled down, E1 was detected in association with all the
E2 mutants.
Discussion
In this study we investigated the role of conserved,
charged amino acid residues in three putative CD81 bind-
ing regions of HCV E2: region 1: amino acid 474–492,
region 2: position 522–551 and putative region 3: amino
acids 612–619 [35-39]. The 20 alanine substitution
mutants characterized in this study can be classified into
those displaying wt characteristics (high infectivity [≥
50% of wt HCVpp], CD81 binding, E1E2 expression,
association, and incorporation into viral particles) or seg-
Binding of mutant HCV E1E2 glycoproteins to soluble CD81 Figure 4
Binding of mutant HCV E1E2 glycoproteins to soluble CD81. (A) 293T cells transfected with HCV E1E2 wt or mutant 
expression vectors were lysed 24 h post-transfection. Cleared cell lysate was incubated with soluble CD81-GST fusion pro-
tein. Binding to CD81 was determined by Western Blot analysis of E2 and the GST tag. As a negative control, GST protein 
without soluble CD81 was incubated with HCV wt. Image is a composite. (B) 293T cells transfected with HCV E1E2 wt or spe-
cific mutant expression vectors were lysed 24 h post-transfection. Cleared cell lysate was incubated with AR3A (C1) confor-
mational antibody to assess conformation of mutations. Immunoprecipitated proteins were detected by subsequent Western 
Blot analysis of E2. Image is a composite.
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regated into 4 distinct low infectivity (≤ 50% of wt
HCVpp) mutant phenotypes: (I) CD81 binding deficient
(despite wt E1E2 expression, incorporation and associa-
tion and proper conformation); (II) CD81 binding com-
petent, but cannot detect E1 on the viral particle (despite
adequate E1E2 expression in producer cell lysates and
proper conformation); (III) CD81 binding competent,
with adequate E1E2 expression, incorporation, associa-
tion, and conformation (i.e. no defect identified to
explain the reduced infectivity observed); (IV) uninforma-
tive mutants with potential disruptions in protein confor-
mation (see Table 1). With only 2 mutations (W487A and
W549A) appearing to result in pseudotyped particles lack-
ing E1, most infectivity deficient alanine substitutions fell
into the first or third group (i.e. CD81 binding defective
or unexplained defect, respectively).
Overall, our results support the notion that putative CD81
binding regions 2 and 3 are involved in CD81 binding as
5 class I mutants (Y527A, W529A, Y613A, H617A and
Y618A) (see Fig. 4) demonstrate a defect in CD81 binding
while maintaining proper conformation. Eleven of the
twenty mutations are defective for infection (see Fig. 2),
independent of CD81 binding and conformation (classes
II and III) (see Table 1), suggesting that these E2 residues
are involved in other essential aspects of HCV entry. All
infectivity deficient mutations within the first putative
CD81 binding region, with the exception of W487A,
belong to the CD81 binding competent group III mutants
for which we do not know why they are defective (see Fig.
2 and 4), indicating that this region, although important
for HCV entry, is not directly involved in CD81 binding.
In contrast, the majority of infectivity defective substitu-
tions in the putative CD81 binding regions 2 (Y527A,
W529A and D535A) and 3 (Y613A, R614A, W616A,
H617A and Y618A) demonstrate little to no CD81 bind-
ing, consistent with these regions being involved in CD81
binding. Whereas D535A, R614A and W616A all dis-
played a disrupted AR3A epitope in this region, indicative
of more global structural aberrances Y527A, W529A,
Y613A, H617A and Y618A have intact conformation and
still are unable to bind CD81, defining these residues as
critical for the HCV E2 and CD81 interaction. In addition,
both regions 2 and 3 contain at least one group III muta-
tion that reduces infectivity, but maintains the ability to
bind CD81 (e.g. D533A, F550A, and L615A). Thus, it is
likely that regions 2 and 3 are also involved in other
aspects of viral entry. Notably, this is in agreement with a
report by Owsianka et al. [54], which examined some of
the same mutants in this region. While the degree of infec-
tivity or CD81 binding quantified for the D533A and
F550A mutants, respectively varied between the two stud-
ies, the phenotype of the mutants and conclusions drawn
are qualitatively consistent
The first and third putative CD81 binding domains tar-
geted, both contain a "WHY" motif. The first "WHY"
motif (487–489) has been implicated in dimerization
[52] and the second "WHY" motif (616–618) falls within
region 600–620, which has been demonstrated to be
involved in fusion [55]. Alanine substitution of any resi-
dues within either two of these motifs resulted in com-
plete elimination of HCVpp infectivity. Consistent with a
possible role of the region 1 "WHY" motif in proper E1E2
dimerization, Western Blot analysis of W487A HCVpp
showed that substitution of tryptophan at position 487
Determining association of E1E2 mutants Figure 5
Determining association of E1E2 mutants. 293T cells were transfected with HCV E1E2 wt, mutant, or E1 alone glyco-
protein expression plasmids. Cells were lysed and cleared cell lysate was incubated with anti (α)-E2 antibody. Immune com-
plexes were separated by SDS-PAGE and analyzed by Western Blot for E1 to determine if the E2 and E1 glycoproteins had 
formed dimers. Image is a composite.
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resulted in an inability to detect the E1 epitope on
HCVpp, despite the presence of E1 in producer cell lysate
(see Fig. 3A). Although Lavillette et al. [55] observed a loss
of both E1 and E2 glycoprotein incorporation into mutant
W487A HCVpp particles, while we still detected E2 on
HCVpp, our inability to detect E1 on W487A particles
resulted in the classification of W487A as a group II
mutant (i.e. a mutant exhibiting a defect in HCV glycopro-
tein incorporation), and is hence consistent with the pre-
vious report. In contrast, both H488A and Y489A mutants
within region 1 did not appear to disrupt E1E2 interaction
and were thus categorized as group III (i.e. no identifiable
defect to explain loss of infectivity) (see Table 1).
Unlike the mutations within the region 1 "WHY" motif,
CD81 binding was disrupted in all three alanine substitu-
tions within the "WHY" motif of the third region (see Fig.
4). Mutation W616A however was not recognized in the
AR3A immunoprecipitation assay, indicating that the
structure of the CD81 binding epitope may have been dis-
rupted. Therefore W616A was grouped as class IV. While
lower amounts of both the H617A and Y618A mutants
were captured by the AR3A antibody, suggesting that fold-
ing of these mutant proteins might be less efficient than
wt, there was a population of these mutant proteins which
retained this conformational epitope and could thus be
analyzed for CD81 binding ability. In contrast to the
H488A and Y489A mutants within region 1 however, the
H617A and Y618A mutants in region 3 demonstrated
reduced CD81 binding classifying then as group I mutants
and implicating them as being directly involved in E2
binding to CD81.
In conclusion, we have determined that the second and
third putative CD81 binding regions are responsible for
mediating E2 binding CD81. In the second region, resi-
dues Y527, W529 and D535 are critical for CD81 binding.
The third putative CD81 binding region comprises a
CD81 binding region, as all alanine substitutions, aside
from L615A, are unable to interact with CD81. This region
is conserved across genotypes, underlining its signifi-
cance. Finally, we have determined that the first putative
CD81 binding region is not a CD81 binding region, as all
mutations bind CD81 at wt levels.
Methods
Cell lines and antibodies
293T human embryonic kidney cells were maintained in
Dulbecco's modified Eagle's media (DMEM) supple-
mented with 10% fetal calf serum with penicillin, strepto-
mycin. Huh7 and Hep3B cells were maintained in DMEM
supplemented with 10% fetal calf serum, penicillin, strep-
tomycin and supplemented with 5 ml Hepes (1 M)
(Gibco), and Nonessential amino acids (NEAA) (Gibco).
The goat polyclonal antibody against hepatitis C virus
(HCV) E2 and the monoclonal mouse antibody for E1
Table 1: 
HCVpp Infect. Infectivity (%) Cellular Express. HCVpp E1E2 Detection E1E2 Assoc. CD81-GST Binding Conform. Group
Huh7 Hep3B E2 E1 E2
WT +++ 100 100 +++ ++ +++ + +++ +++ wt
Y474A ++ 77 36 +++ +++ ++++ + +++ NA wt&III
D481A +++ 64 71 +++ + ++++ ++ +++ NA wt
R483A - 2 1 +++ + ++++ ++ ++++ good III
Y485A - 2 1 +++ + ++++ + +++ good III
W487A - 1 0 +++ - ++++ + +++ +++ II
H488A - 2 1 +++ +++ ++++ + +++ good III
Y489A - 4 2 +++ +++ +++ ++ ++++ good III
R492A - 5 2 +++ + ++++ + +++ NA III
Y527A - 5 1 + ++++ + + - +++ I
W529A - 1 1 ++ ++++ ++++ +++ - ++ I
D533A - 12 5 ++ ++++ ++++ + +++ +++ III
D535A - 2 0 ++ +++ +++ ++ - - IV
W549A - 2 0 + - ++++ ++++ +++ +++ II
F550A - 19 2 ++ + +++ ++++ ++ good III
Y613A - 3 1 + + +++ ++ - +++ I
R614A - 3 0 + ++ ++++ ++++ - - IV
L615A + 44 10 + + ++++ +++ ++ NA III
W616A - 2 0 + + +++ + - - IV
H617A - 2 0 + ++ + +++ - + I
Y618A - 2 1 + + ++++ +++ +/- + I
+ and - denote the properties of wt and mutants of HCV E2
"NA" indicates mutations not screened in this study and "good" indicates mutants screened in previous study [45]Virology Journal 2008, 5:46 http://www.virologyj.com/content/5/1/46
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glycoproteins (GP) (genotype 1a) were obtained through
ViroStat. The mouse anti-HIV p24 monoclonal antibody
was obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program. Polyclonal rab-
bit glutathione-S-transferase (GST) antibody was
obtained from NeoMarkers. The conformational anti-E2
AR3A antibody was provided by Dennis Burton, PhD
from The Scripps Research Institute.
Mutagenesis of the HCV E2 glycoprotein gene
The cDNA clone containing E1E2 from genotype 1a strain
H77 in pCB6, was kindly provided by Charles Rice, PhD
(Rockefeller University). All alanine substitution muta-
tions of the HCV E2 glycoprotein were generated by site-
directed mutagenesis with the Stratagene Quick-Change
mutagenesis kit according to the supplier's protocols. All
mutations were confirmed by DNA sequencing.
Pseudotyping
Pseudotyped viruses were produced by cotransfecting
DNA encoding wild-type (wt) or mutant glycoproteins
with the Env-deficient HIV vector carrying a luciferase
reporter gene (pNL4-3-Luc-R--E-) into 293T producer
cells. One microgram of the wt or mutant glycoprotein
expression plasmid and 3 µg of pNL4-3-Luc-R--E- were
used to transfect 293T cells (90% confluent) in 6-well
plates with polyethylenimine (PEI). The DNA cocktail was
added to 200 µl Opti-MEM media and PEI was added at
2× the volume of DNA. The mixture was incubated at
room temperature for 15 min. 293T producer cells were
rinsed with PBS (no Ca++/no Mg++). Eight hundred micro-
liters of Opti-MEM was added to each well and the PEI/
DNA mixture was added. After 5–6 h incubation at 37°C,
the DNA cocktail was aspirated off and 3 ml cell culture
media was added per well. A minimum of two wells per
mutant were done at each time, for a total of 6 ml. The
supernatants containing the pseudotyped viruses were
collected 48 h posttransfection and filtered through a 0.45
µm-pore-size filter (Nalgene).
Pseudotyped virus infectivity assay
Huh7 or Hep3B cells were seeded in 12-well plates at a
density of 8 × 104 per well one day prior to infection. Cells
were incubated with 500 µl of pseudotyped virus for 6 h,
then virus was removed and cell growth media was added.
The cells were lysed in 100 µl of cell culture lysis reagent
(Promega) at 72 h post-infection (PI). The luciferase activ-
ity was measured with a luciferase assay kit (Promega) and
a FB12 luminometer (Berthold detection system) accord-
ing to supplier's protocol. Each sample was done in dupli-
cate and experiments were repeated at least three times.
Western Blot analysis
To determine HCV E1E2 expression and incorporation,
293T producer cells transfected with HCV E1E2/HIV plas-
mids as described above, were lysed in 0.5 ml of 1% Tri-
ton X-100 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 5 mM EDTA) and protease inhibitor cocktail (10
µg/ml leupeptin and pepstatin, 5 µg/ml aprotinin and 2
mM phenylmethylsulfonyl fluoride) after harvesting virus
and rinsing cells with PBS (no Ca++/no Mg++). The protein
samples were spun down at 14 k for 10 min to clear cellu-
lar debris and transferred to fresh eppendorf tubes. SDS-
PAGE loading dye was added to the protein samples,
which were subsequently boiled for 5 min at 95°C, fol-
lowed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to a polyvinyl
difluoride membrane (PVDF). Membranes were then
probed for HCV glycoproteins E1 and E2 and actin, p24 or
GST using peroxidase-conjugated secondary antibody and
chemiluminescence reagent according to the supplier's
protocol (SuperSignal West pico chemiluminescent sub-
strate, Pierce). To determine incorporation of E1 and E2
into the pseudotyped viruses, 4 ml of pseudotyped virus
was layered onto a 1 ml cushion of 20% sucrose in PBS
and centrifuged at 55,000 rpm for 45 min in a SW55Ti
rotor (Beckman Coulter) at 16°C. The pelleted pseudovir-
ions were lysed in 50 µl of 1% Triton X-100 lysis buffer
and subjected to SDS-PAGE and Western Blot analysis.
CD81 binding assay
The CD81 clone used was kindly provided by Shoshana
Levy, PhD (Stanford University). A glutathione S-trans-
ferase (GST) fusion protein containing the large extracel-
lular loop (LEL) of human CD81 was generated as
previously described [4]. 293T producer cells were trans-
fected with 1 µg HCV E1E2 DNA using PEI. After 48 h cells
were lysed in 0.5% Triton X-100 lysis buffer with protease
inhibitor on ice for 30 min. Cell lysates were clarified by
centrifuging at 20,000 × g for 30 min at 4°C. Two-hun-
dred microliters of clarified lysates from these cells were
incubated with 5 µg of CD81-GST fusion protein or GST
protein alone with gentle rocking at 4°C for 16 h. Fifty
microliters of Glutathione Sepharose 4B (GSH) beads (GE
Healthcare) rinsed three times with PBS (140 mM NaCl,
27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) were
added and incubated at 4°C for 1 h. The slurry was spun
down for 1 min at 14, 000 rpm and GSH beads were
rinsed two times with 0.5% Triton X-100 lysis buffer. SDS-
PAGE loading dye was added to the beads and samples
were boiled at 95°C for 5 min. Slurry was spun down
again and supernatant was collected for SDS-PAGE and
Western Blot analysis.
E2 conformational antibody immunoprecipitation
293T producer cells were transfected with 1 µg wt or a
selection of CD81 binding deficient or binding competent
mutant HCV E1E2 DNA constructs using PEI. After 48 h
cells were lysed in 0.5% Triton X-100 lysis buffer with pro-
tease inhibitor on ice for 30 min. Cell lysates were clari-Virology Journal 2008, 5:46 http://www.virologyj.com/content/5/1/46
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fied by centrifuging at 20,000 × g for 30 min at 4°C. Four-
hundred microliters of clarified lysates from these cells
were incubated with 1 µg of AR3A conformational anti-
body [45] with gentle rocking at 4°C for 16 h. Immobi-
lized protein A (Pierce) beads were rinsed three times with
PBS (140 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4). Fifty microliters of rinsed polyA beads
were then added to the cell lysate/antibody cocktail and
incubated with gentle rocking at 4°C for 2 h. Beads were
washed three times with 100 µl 0.5% Triton lysis buffer.
SDS-PAGE loading dye was added to the beads and sam-
ples were boiled at 95°C for 5 min. Slurry was spun down
and supernatant was collected for SDS-PAGE separation
and Western Blot analysis with a polyclonal anti E2 anti-
body (Virostat).
E1E2 association pull-down
293T producer cells were transfected with 1 µg HCV E1E2
expression plasmid using PEI. Forty-eight h post-transfec-
tion cells were lysed in 4% Triton X-100 lysis buffer (4%
Triton X-100, 100 mM Tris HCl [pH 8.0], 1 mM EDTA)
[56] with protease inhibitor for 30 min on ice. Cell lysates
were clarified by centrifuging at 20,000 × g for 30 min at
4°C. Five-hundred microliters of cell lysate was incubated
with 5 µg ViroStat polyclonal, goat anti-E2 antibody for
16 h at 4°C with gentle rocking. Immobilized protein A
(Pierce) beads were rinsed three times with PBS (140 mM
NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4).
Fifty microliters polyA beads were then added to the cell
lysate/antibody cocktail and incubated with gentle rock-
ing at 4°C for 2 h. Beads were washed four times with 100
µl PBS with 0.2% Triton. SDS-PAGE loading dye was
added to the beads and samples were boiled at 95°C for 5
min. Slurry was spun down and supernatant was collected
for SDS-PAGE separation and Western Blot analysis with
anti E1 antibody (Virostat).
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